You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lipoprotein(a)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Oxidized Low Density Lipoprotein Trial in Fort Lauderdale (Cardio formulation, Placebo)

Terminated
  • Oxidized Low Density Lipoprotein
  • Cardio formulation
  • Placebo
  • Fort Lauderdale, Florida
    Lfie Extension Clinical Reseach, Inc.
Jan 12, 2023

LDL Hyperlipoproteinemia, Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia, Triglyceride Storage Type I or II Disease

Not yet recruiting
  • LDL Hyperlipoproteinemia
  • +2 more
  • omega-3 fatty acids
  • Placebo
  • Novosibirsk, Novosibisk Region, Russian Federation
    Center of New Medical Technologies
Nov 30, 2023

Lipid Profile in Acute Coronary Syndrome

Not yet recruiting
  • Acute Coronary Syndrome
  • Triglycerides/high density lipoprotein ratio
  • (no location specified)
Nov 17, 2021

Lipoprotein Disorder Trial in Worldwide (LY3819469, Placebo)

Recruiting
  • Lipoprotein Disorder
  • Mesa, Arizona
  • +81 more
Jan 18, 2023

Low-density Lipoprotein Cholesterol Levels in Coronary Heart

Completed
Has Results
  • Hypercholesterolemia
  • (no location specified)
Feb 7, 2022

Coronary Artery Disease, Diabetes, Metabolic Syndrome Trial in Storrs (Consume 2 eggs with spinach per day, Egg Subsitute with

Completed
  • Coronary Artery Disease
  • +2 more
  • Consume 2 eggs with spinach per day
  • Egg Subsitute with spinach per day
  • Storrs, Connecticut
    Department of Nutritional Sciences
Nov 1, 2022

Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome Trial in Dallas (RVX000222, Placebo)

Completed
  • Dyslipidemia
  • +3 more
  • Dallas, Texas
    Covance Clinical Research Unit, Inc.
Nov 1, 2022

Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia Trial in Yongin (Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg)

Recruiting
  • Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
  • Evolocumab 140 MG/ML
  • +2 more
  • Yongin, Gyeonggi-do, Korea, Republic of
    Yongcheol Kim
Jan 6, 2023

NASH (Nonalcoholic Steatohepatitis), NAFLD (Nonalcoholic Fatty Liver Disease) Trial (PF-05221304, Placebo)

Withdrawn
  • NASH (Nonalcoholic Steatohepatitis)
  • NAFLD (Nonalcoholic Fatty Liver Disease)
  • (no location specified)
Aug 19, 2021

Cerebral Hemorrhage Trial in Shenyang (Delipid Extracorporeal Lipoprotein filter from Plasma)

Terminated
  • Cerebral Hemorrhage
  • Delipid Extracorporeal Lipoprotein filter from Plasma
  • Shenyang, China
    Department of Neurology, General Hospital of Northern Theater Co
Oct 28, 2021

Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density

Active, not recruiting
  • Atherosclerotic Cardiovascular Disease
  • +2 more
  • Sale, Cheshire, United Kingdom
  • +16 more
Jan 20, 2023

Overweight and Obesity Trial in San Francisco (High sugar/meal feed, High sugar/nibble, High fat/meal feed)

Active, not recruiting
  • Overweight and Obesity
  • High sugar/meal feed
  • +5 more
  • San Francisco, California
    University of California, San Franciso, San Francisco General Ho
May 17, 2022

Dyslipidemia, Hypercholesterolemia Trial in Seoul (Test Meal)

Completed
Has Results
  • Dyslipidemia
  • Hypercholesterolemia
  • Test Meal
  • Seoul, Korea, Republic of
    MSD Korea Ltd.
Feb 7, 2022

Improving Systolic BP and LDL-C Compared to Conventional

Not yet recruiting
  • Hyperlipidemias
  • Hypertension
  • Rosuvastatin, Olmesartan Medoxomil
  • (no location specified)
Jun 6, 2022

Hypercholesterolemia Trial in Adelaide (Swisse Nutra+ Cholesterol Balance, Placebo)

Completed
  • Hypercholesterolemia
  • Swisse Nutra+ Cholesterol Balance
  • Placebo
  • Adelaide, South Australia, Australia
    CSIRO Nutrition and Health Research Clinic
Mar 9, 2022

Atherosclerotic Cardiovascular Disease Trial in Worldwide (Placebo, Olpasiran)

Recruiting
  • Atherosclerotic Cardiovascular Disease
  • Huntsville, Alabama
  • +83 more
Feb 1, 2023

Healthy Participants Trial in Richmond (SP16, Placebos)

Completed
  • Healthy Participants
  • Richmond, Virginia
    Virginia Commonwealth University
Jul 26, 2021

Function of High Density Lipoproteins in Acute Coronary

Active, not recruiting
  • Acute Coronary Syndrome
    • Montreal, Quebec, Canada
      McGill University Health Centre
    Sep 22, 2021

    Hyperlipidemia Trial in Changsha, Chengdu, Beijing (100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), Placebo, 300 mg

    Completed
    • Hyperlipidemia
    • 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
    • +2 more
    • Changsha, Hunan, China
    • +2 more
    Dec 2, 2021

    Coronary Disease Trial (MK0653, ezetimibe / Duration of Treatment: 27 Weeks, MK0733, simvastatin / Duration of Treatment: 27

    Completed
    • Coronary Disease
    • MK0653, ezetimibe / Duration of Treatment: 27 Weeks
    • +2 more
    • (no location specified)
    Feb 7, 2022

    A Multi-center, Prospective, Observational Study to Describe

    Not yet recruiting
    • Lipoprotein Disorder
      • (no location specified)
      Oct 5, 2021

      Sedentary Lifestyle, Hyperinsulinemia, Glucose Tolerance Impaired Trial in Houston (Muscular Exercise)

      Active, not recruiting
      • Sedentary Lifestyle
      • +7 more
      • Muscular Exercise
      • Houston, Texas
        University of Houston
      Nov 19, 2021

      Hypercholesterolemia, Atherosclerosis Trial (Ezetimibe, Placebo)

      Terminated
      • Hypercholesterolemia
      • Atherosclerosis
      • (no location specified)
      Feb 7, 2022

      Predictor of No-reflow in Diabetic Patients

      Not yet recruiting
      • Acute Myocardial Infarction (AMI)
      • 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S
      • (no location specified)
      Apr 7, 2021

      Prevalence of Hyperandrogenism in Type 1 Diabetes

      Recruiting
      • Type 1 Diabetes
      • +5 more
      • Clinical hyperandrogenism assessment
      • +20 more
      • Madrid, Spain
        Hospital Universitario Ramón y Cajal
      Mar 14, 2022